Combined Whey Protein and Collagen Supplementation in Resistance-Trained Men

NCT ID: NCT07171411

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-03

Study Completion Date

2024-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tested whether taking whey protein together with collagen peptides would provide greater benefits for muscle and bone health compared to whey protein alone, collagen alone, or a placebo. Forty healthy, resistance-trained men aged 18-35 years were randomly assigned to one of four groups: (1) whey protein plus collagen (30 g + 10 g/day), (2) whey protein only (30 g/day), (3) collagen only (10 g/day), or (4) placebo (maltodextrin). All participants followed a supervised resistance training program (3 times per week) for 8 weeks.

The primary outcome was muscle mass, measured with bioelectrical impedance analysis (BIA). Secondary outcomes included bone mineral density (DXA scans), maximal strength (1RM squat and bench press), and blood markers of bone turnover (P1NP and CTX-I).

Results showed that the whey + collagen group achieved the largest improvements in muscle growth, lumbar spine bone mineral density, strength, and favorable changes in bone turnover markers compared to all other groups. No serious side effects were reported, and supplement adherence was very high.

These findings suggest that combining whey protein and collagen may be a practical strategy to support muscle and bone adaptation in resistance-trained men.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a double-blind, randomized, placebo-controlled trial evaluating the combined effects of whey protein and collagen supplementation on muscle mass, bone mineral density (BMD), muscular strength, and bone turnover markers in resistance-trained men.

Forty healthy male participants (18-35 years, with ≥1 year of resistance training experience) were recruited and randomized into four parallel groups (n=10 per group):

Whey Protein + Collagen (30 g WP + 10 g collagen/day)

Whey Protein only (30 g/day)

Collagen only (10 g/day)

Placebo (10 g maltodextrin/day, isocaloric)

All supplements were provided in identical single-dose sachets to ensure blinding. Participants consumed one dose upon waking and one post-exercise (or same time on rest days). A standardized, supervised hypertrophy-oriented resistance training program (3 sessions/week for 8 weeks) was applied to all groups.

Primary outcome: Muscle mass (lean body mass, assessed with BIA at baseline and 8 weeks).

Secondary outcomes: Lumbar spine and femoral neck BMD (DXA), maximal squat and bench press strength (1RM), and serum biomarkers of bone turnover (P1NP and CTX-I).

The trial was approved by the Islamic Azad University IRB (Protocol No: IAU.Ilk.C.162911421.2024). All participants gave written informed consent. Compliance with supplementation was \>90% and training adherence was \>95%. No adverse events were reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Hypertrophy Bone Mineral Density Loss Resistance Training Adaptation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants were randomly assigned into one of four parallel groups (Whey + Collagen, Whey only, Collagen only, Placebo). Each group received its allocated supplementation daily for 8 weeks in combination with a standardized resistance training program. Groups were followed concurrently with no crossover.
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Double-blind design extended to all relevant parties. Supplements were provided in identical, opaque sachets to ensure concealment. Randomization sequence was managed by an independent statistician not involved in data collection or analysis. Participants, trainers, investigators, and outcome assessors remained blinded to group assignments until completion of analyses.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Whey Protein + Collagen (WP+C)

Participants received 30 g/day whey protein isolate plus 10 g/day type I \& III collagen peptides, split into two daily doses (morning and post-exercise or at same time on rest days). Supplements were packaged in identical sachets.

Group Type EXPERIMENTAL

Whey Protein + Collagen

Intervention Type DIETARY_SUPPLEMENT

Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.

Whey Protein Only (WP)

Participants received 30 g/day whey protein isolate, split into two daily doses. Packaged identically to other interventions to maintain blinding.

Group Type ACTIVE_COMPARATOR

Whey Protein

Intervention Type DIETARY_SUPPLEMENT

Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.

Collagen Only (C)

Participants received 10 g/day type I \& III collagen peptides, split into two daily doses. Identical packaging ensured blinding.

Group Type ACTIVE_COMPARATOR

Collagen Peptides

Intervention Type DIETARY_SUPPLEMENT

Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.

Placebo (P)

Participants received 10 g/day maltodextrin (isocaloric with protein groups), provided in identical sachets to ensure blinding.

Group Type PLACEBO_COMPARATOR

Maltodextrin (Placebo)

Intervention Type OTHER

Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whey Protein + Collagen

Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Whey Protein

Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Collagen Peptides

Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male participants aged 18-35 years
* At least 1 year of consistent resistance training experience (≥3 sessions per week, targeting major muscle groups)
* Healthy, with no history of musculoskeletal, metabolic, or cardiovascular disorders
* No current or recent (\<6 months) use of anabolic steroids, growth hormones, or performance-enhancing substances
* Non-smoker and no habitual use of anti-inflammatory medications
* Able and willing to comply with supplementation and supervised training program
* Provided written informed consent

Exclusion Criteria

* Participation in similar supplementation studies in the past 6 months
* Recent fractures or surgeries affecting musculoskeletal health (\<6 months)
* Known allergy or intolerance to dairy proteins or collagen supplements
* Inability to attend scheduled supervised resistance training sessions
* Non-adherence to dietary control requirements (e.g., use of additional protein/creatine supplements during study)
* Any condition deemed by investigators to interfere with study compliance or safety
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saglik Bilimleri Universitesi

OTHER

Sponsor Role collaborator

Islamic Azad University of Mashhad

OTHER

Sponsor Role collaborator

Manisa Celal Bayar University

OTHER

Sponsor Role collaborator

Muş Alparslan University

OTHER

Sponsor Role collaborator

Pamukkale University

OTHER

Sponsor Role collaborator

Australian Catholic University

OTHER

Sponsor Role collaborator

Ankara Yildirim Beyazıt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Health Sciences

Ankara, Etlik, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IAU.Ilk.C.162911421.2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.